Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 163451-81-8 | Product Number: T3287
Teriflunomide
×
![]()
×
Purity: >98.0%(GC)
Synonyms:
- N-[4-(Trifluoromethyl)phenyl]-2-cyano-3-hydroxycrotonamide
- (Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 100MG |
€48.00
|
1 | 34 |
|
| 1G |
€297.00
|
1 | 34 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | T3287 |
| Purity / Analysis Method | >98.0%(GC) |
| Molecular Formula / Molecular Weight | C__1__2H__9F__3N__2O__2 = 270.21 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 163451-81-8 |
| Reaxys Registry Number | 6655982 |
| PubChem Substance ID | 253661385 |
| Merck Index (14) | 9165 |
| MDL Number | MFCD00910058 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
| Melting point | 227.0 to 231.0 °C |
Properties (reference)
| Melting Point | 229 °C |
| Maximum Absorption Wavelength | 203(MeOH) nm |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
Transport Information:
| HS Number | 2926907090 |
Application
Teriflunomide: An Immunomodulatory Compound
Teriflunomide (A77 1726), the active metabolite of leflunomide [L0250], is an immunomodulatory compound. Teriflunomide has two activites: inhibition of pyrimidine nucleotide synthesis and interference with tyrosine phosphorylation. More specifically, it inhibits the enzymic activity of dihydroorotate dehydrogenase (DHO-DHase) which catalyzes the fourth step in the biosynthesis of pyrimidine, and tyrosine kinases which transfer a phosphate group from ATP to a protein in a cell. Teriflunomide reduces the proliferation of T and B immune cells that are active in multiple sclerosis (MS). For your reference, [C3217] is a synthetic intermediate. (The product is for research purpose only.)
References
- Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound
- The Immunosuppressive Metabolite of Leflunomide Is a Potent Inhibitor of Human Dihydroorotate Dehydrogenase
- The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis (a review)
- Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography
- Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.